In these large cohort studies, DNMT3A and TET2 mutations appeared as commonly occurring events in both AML and control cases, but higher VAFs (> 10%), the presence of a higher number of variants (two or more), along with clonal complexity, correlated with a greater risk of AML [53•, 54•]. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.